3/22/2022

speaker
Operator
Conference Call Operator

Greetings. Welcome to CINCOR Pharma's fourth quarter and full year 2021 financial results and corporate update conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, March 22, 2022. I will now turn the call over to Terry Qualho, Executive Vice President, Chief Financial Officer, and Chief Business Development Officer. Terry, please go ahead.

speaker
Terry Qualho
Executive Vice President, Chief Financial Officer, and Chief Business Development Officer

Good morning and welcome to CINCOR Pharma's fourth quarter and full year 2021 financial results and corporate updates conference call. Joining me on today's call are Mark DeGaradale, Chief Executive Officer, and Dr. Mason Freeman, Chief Medical Officer. We will hold a question and answer session following our prepared remarks where Catherine Pierce, our co-founder and Chief Operating Officer, and Justin Thompson, our Vice President of Business Development, will join as well. Earlier today, CINCOR issued a press release announcing financial results for the fourth quarter and full year ended December 31st, 2021. A copy of this press release is available on the company's website and through our SEC filing. Please note that on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic commercial potential and regulatory status of our investigational product candidates, the expected timing of our clinical trials, results, milestones, sufficiency of CINCOR's cash resources, expectations with respect to CINCOR's growth and prospects, and statements with respect to human capital, among others. Various risks may cause CINCOR's actual results to differ materially from those stated or implied in such forward-looking statements. For a description of the risks and uncertainties that we face, please see our earnings press release issued earlier today and our risk factors contained in our filings with the Securities and Exchange Commission. including the risk factor section of our annual report on Form 10-K that we expect to file with the SEC later today. This conference call contains time-sensitive information that is accurate only as of the date of such information and our expectations as of the date of this live conference call, March 22, 2022. NCORE undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. A live listen-only audio webcast of the conference call can be accessed on the investor section of the Syncor Pharma, Inc. website. A replay will be available on the website approximately two hours following the live call for 30 days following the call. I will now turn the call over to our CEO, Mark DeGaradale. Mark, please go ahead.

speaker
Mark DeGaradale
Chief Executive Officer

Thank you, Terry. Good morning and welcome, everyone, to our first corporate update and financial results conference call. 2021 was a transformative year for us, and we have made significant progress across our corporate and clinical initiatives. We first provide a brief overview of the company before I turn the call over to Mason to review our clinical development programs, which will then be followed by a financial update from Terry. 2021 was a highly successful and foundational year for the company that was marked by many significant milestones. In October, we raised approximately $142 million net proceeds through Series B financing that included a number of high-quality healthcare-focused investors. We subsequently completed a successful IPO in early January, raising approximately $192 million net proceeds and attracting several new institutional investors. We expect our strength and balance sheet to provide a cash runaway through 2024 based on our current business plans, positioning us well to further execute on the ongoing clinical development of SYN107. There are four key takeaways regarding SYNCORE that I want you to list today. We have a focused and differentiated pipeline. We believe we have a robust potential market opportunity. We have multiple anticipated near-term catalysts in 2022 and 2023. And we have an experienced management team and a strong balance sheet. Our molecule CIN107 is a highly selective aldosterone synthase inhibitor. De-risked with phase 1 and blinded phase 2 clinical data. Promising early efficacy has been demonstrated by dose-dependent reduction in aldosterone levels in phase 1 trials following treatment with CIN107 and by reduction in systolic blood pressure and preliminary blinded safety data from the ongoing phase 2 Brighton trials which included two active doses and placebo. As we know, safety is critical for adoption of a drug, and we are pleased to report that with nearly 400 patients dosed across multiple clinical trials, we have observed a favorable safety profile in Phase I and Phase II studies to date, with no clinically meaningful impact on cortisol and no significant electrolyte-related adverse events. Additionally, As an all-once-daily small molecule, we believe C107 has an ideal dosing profile for chronic cardiovascular drugs. The second key takeaway relates to the potential market opportunity for C107, which we believe is robust and includes a broad patient population with significant unmet needs in hypertension, CKD patients with hypertension, and primary aldosteronism. As an example, it is estimated that 12 to 15 million patients in the U.S. are treatment-resistant. Treatment-resistant means patients are on at least three antihypertensive agents and are still not a target blood pressure goal. Thirdly, SYNCOR anticipates multiple near-term catalysts in 2022 and 2023. I am very pleased to share that we completed enrollment in the Phase II Brighton trial of treatment-resistant hypertension this month. with 275 patients randomized. In terms of data readouts, we expect top-line phase two data for both the Brighton trial and the Ello trial for uncontrolled hypertension on one or two background therapies are expected in the second half of 2022 and in 2023 for SPARC-PA for primary aldosteronism. This year, we're also excited to explore the dual potential of CIN107 to improve uncontrolled blood pressure with a planned initiation of a fourth phase 2 trial for patients with CKD. Finally, our experienced leadership team has a solid track record of success, notably in the cardiovascular field. We are also pleased to have named Dr. Mason Freeman as our Chief Medical Officer this month. Mason was EVP of Clinical Development since August 2021. Following our Series B financing and a successful IPO, We are well-signed and believe we are poised to successfully advance our business to the next phase of growth. Let me now turn the call over to Dr. Mason Freeman, our Chief Medical Officer, who will provide an overview of the unmet medical need, the science around aldosterone, and review our clinical development programs. Mason, please go ahead.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-